Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes : an observational multicentre study
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA..
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have cardioprotective and renoprotective effects. However, experience with SGLT2is in diabetic kidney transplant recipients (DKTRs) is limited.
Methods: This observational multicentre study was designed to examine the efficacy and safety of SGLT2is in DKTRs. The primary outcome was adverse effects within 6 months of SGLT2i treatment.
Results: Among 339 treated DKTRs, adverse effects were recorded in 26%, the most frequent (14%) being urinary tract infection (UTI). In 10%, SGLT2is were suspended mostly because of UTI. Risk factors for developing a UTI were a prior episode of UTI in the 6 months leading up to SGLT2i use {odds ratio [OR] 7.90 [confidence interval (CI) 3.63-17.21]} and female sex [OR 2.46 (CI 1.19-5.03)]. In a post hoc subgroup analysis, the incidence of UTI emerged as similar in DKTRs treated with SGLT2i for 12 months versus non-DKTRs (17.9% versus 16.7%). Between baseline and 6 months, significant reductions were observed in body weight [-2.22 kg (95% CI -2.79 to -1.65)], blood pressure, fasting glycaemia, haemoglobin A1c [-0.36% (95% CI -0.51 to -0.21)], serum uric acid [-0.44 mg/dl (95% CI -0.60 to -0.28)] and urinary protein:creatinine ratio, while serum magnesium [+0.15 mg/dl (95% CI 0.11-0.18)] and haemoglobin levels rose [+0.44 g/dl (95% CI 0.28-0.58]. These outcomes persisted in participants followed over 12 months of treatment.
Conclusions: SGLT2is in kidney transplant offer benefits in terms of controlling glycaemia, weight, blood pressure, anaemia, proteinuria and serum uric acid and magnesium. UTI was the most frequent adverse effect. According to our findings, these agents should be prescribed with caution in female DKTRs and those with a history of UTI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical kidney journal - 16(2023), 6 vom: 26. Juni, Seite 1022-1034 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sánchez Fructuoso, Ana I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 04.06.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ckj/sfad007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357630904 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357630904 | ||
| 003 | DE-627 | ||
| 005 | 20231226073019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ckj/sfad007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357630904 | ||
| 035 | |a (NLM)37260993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sánchez Fructuoso, Ana I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes |b an observational multicentre study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.06.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have cardioprotective and renoprotective effects. However, experience with SGLT2is in diabetic kidney transplant recipients (DKTRs) is limited | ||
| 520 | |a Methods: This observational multicentre study was designed to examine the efficacy and safety of SGLT2is in DKTRs. The primary outcome was adverse effects within 6 months of SGLT2i treatment | ||
| 520 | |a Results: Among 339 treated DKTRs, adverse effects were recorded in 26%, the most frequent (14%) being urinary tract infection (UTI). In 10%, SGLT2is were suspended mostly because of UTI. Risk factors for developing a UTI were a prior episode of UTI in the 6 months leading up to SGLT2i use {odds ratio [OR] 7.90 [confidence interval (CI) 3.63-17.21]} and female sex [OR 2.46 (CI 1.19-5.03)]. In a post hoc subgroup analysis, the incidence of UTI emerged as similar in DKTRs treated with SGLT2i for 12 months versus non-DKTRs (17.9% versus 16.7%). Between baseline and 6 months, significant reductions were observed in body weight [-2.22 kg (95% CI -2.79 to -1.65)], blood pressure, fasting glycaemia, haemoglobin A1c [-0.36% (95% CI -0.51 to -0.21)], serum uric acid [-0.44 mg/dl (95% CI -0.60 to -0.28)] and urinary protein:creatinine ratio, while serum magnesium [+0.15 mg/dl (95% CI 0.11-0.18)] and haemoglobin levels rose [+0.44 g/dl (95% CI 0.28-0.58]. These outcomes persisted in participants followed over 12 months of treatment | ||
| 520 | |a Conclusions: SGLT2is in kidney transplant offer benefits in terms of controlling glycaemia, weight, blood pressure, anaemia, proteinuria and serum uric acid and magnesium. UTI was the most frequent adverse effect. According to our findings, these agents should be prescribed with caution in female DKTRs and those with a history of UTI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SGLT2 inhibitors | |
| 650 | 4 | |a post-transplant diabetes mellitus | |
| 650 | 4 | |a type 2 diabetes | |
| 700 | 1 | |a Bedia Raba, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Banegas Deras, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Vigara Sánchez, Luis A |e verfasserin |4 aut | |
| 700 | 1 | |a Valero San Cecilio, Rosalía |e verfasserin |4 aut | |
| 700 | 1 | |a Franco Esteve, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Cruzado Vega, Leonidas |e verfasserin |4 aut | |
| 700 | 1 | |a Gavela Martínez, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a González Garcia, María E |e verfasserin |4 aut | |
| 700 | 1 | |a Saurdy Coronado, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Nancy D Valencia |e verfasserin |4 aut | |
| 700 | 1 | |a Zarraga Larrondo, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Ridao Cano, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Mazuecos Blanca, Auxiliadora |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández Marrero, Domingo |e verfasserin |4 aut | |
| 700 | 1 | |a Beneyto Castello, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Paul Ramos, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra Ochoa, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Facundo Molas, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a González Roncero, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Torres Ramírez, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Cigarrán Guldris, Secundino |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Flores, Isabel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical kidney journal |d 2012 |g 16(2023), 6 vom: 26. Juni, Seite 1022-1034 |w (DE-627)NLM219739579 |x 2048-8505 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:6 |g day:26 |g month:06 |g pages:1022-1034 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ckj/sfad007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 6 |b 26 |c 06 |h 1022-1034 | ||